Heptares Therapeutics
Richard Mould has extensive work experience in the pharmaceutical industry. Richard started their career at Pfizer in 2007 as an In-vitro Pharmacologist, where they worked until 2008. Richard then joined Astex Therapeutics as an Associate Enzymologist for a year. In 2009, they joined Sosei Heptares as a Senior Scientist, responsible for overseeing and carrying out various projects related to GPCR. Richard'srole involved screening and pharmacological profiling, management of ADME screening, and engagement with medicinal and computational chemistry. Richard has been working at MSD since 2019 as a Senior Scientist.
Richard Mould obtained their Bachelor of Science (BSc) degree in Applied Biology from the University of Reading, where they studied from 2002 to 2005.
Heptares Therapeutics
Heptares Therapeutics is a drug discovery company focused on novel small-molecule drugs targeting G-protein-coupled receptors (GPCRs), the largest family of druggable targets.The Company has developed a unique, transformational and proprietary technology for making purified, stabilised and functional GPCRs (known as StaRs, StabilisedReceptors), overcoming a major limiting factor to the development of new drugs targeting this group.